Abingdon Health PLC AGM Statement (6837W)
15 December 2023 - 6:00PM
UK Regulatory
TIDMABDX
RNS Number : 6837W
Abingdon Health PLC
15 December 2023
Abingdon Health plc
("Abingdon Health" or "the Company")
AGM Statement
York, U.K. 15 December 2023: Abingdon Health plc (AIM: ABDX,
'Abingdon' or 'the Company'), a leading international lateral flow
contract research (CRO) and contract development and manufacturing
organisation (CDMO), will hold its Annual General Meeting at 9.30
a.m. today at the Company's facilities at York Biotech Campus, Sand
Hutton, York, YO41 1LZ.
Chris Yates, Chief Executive Officer, will address the meeting
with the following statement: "We updated shareholders in October
with our annual results to June 2023. At that time, I said that I
believed Abingdon was well positioned to meet the growing demand of
the lateral flow market, through both our CRO/CDMO offering, and
through our complementary direct sales and distribution platform.
This is proving to be the case as evidenced both by the number of
customers and projects we are working with, and our continued
revenue growth. We will provide a more comprehensive trading update
in January 2024, but I am pleased to note that our revenue for H1
FY23/24 will be significantly higher than revenue for H1
FY22/23."
"We remain highly focused on continuing to grow our revenues and
reducing our cash-burn in FY23/24 and beyond. Our ongoing priority
is moving the Company to a positive cash flow position based on
continued revenue growth and stringent cost control."
Enquiries
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Via Walbrook PR
Officer
Chris Hand, Non-Executive
Chairman
Singer Capital Markets (Sole Tel: +44 (0)20 7496 3000
Broker and Nominated Adviser)
Peter Steel, Alex Bond (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Phillip Marriage Mob: +44 (0)7980 541 893 / +44 (0)7867 984
Alice Woodings 082
+44 (0)7407 804 654
About Abingdon Health plc
Abingdon Health is a leading lateral flow contract research
(CRO) and contract development and manufacturing organisation
("CDMO") offering its services to an international customer base
across industry sectors that include clinical, animal health, plant
health, and environmental testing. Abingdon Health has the internal
capabilities to take projects from initial concept through to
routine and large-scale manufacturing; from "idea to commercial
success."
The Company's CDMO division offers product development,
regulatory support, technology transfer and manufacturing services
for customers looking to develop new assays or transfer existing
laboratory-based assays to a lateral flow format. Abingdon Health
aims to support the increase in need for rapid results across many
industries and locations and produces lateral flow tests in areas
such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes.
Abingdon Health's Abingdon Simply Test(TM) range of self-tests
is an ecommerce platform that offers a range of self-tests to
empowers consumers to manage their own health and wellbeing. The
Abingdon Simply Test (TM) ecommerce site offers consumers a range
of information to support them in making informed decisions on the
tests available. In addition, the site provides Abingdon's contract
services customers with a potential route to market for self-tests.
The Abingdon Simply Test range is also sold through international
distributors and through other channels in the UK and Ireland such
as pharmacy chains.
Founded in 2008, Abingdon Health is headquartered in York,
England.
For more information visit: www.abingdonhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGMNKNBPNBDDNBD
(END) Dow Jones Newswires
December 15, 2023 02:00 ET (07:00 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Apr 2024 to May 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From May 2023 to May 2024